Cetrorelix 0.25 Mg Injection

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cetrorelix 0.25 mg injection in China. Welcome to wholesale bulk high quality cetrorelix 0.25 mg injection for sale here from our factory. Good service and reasonable price are available.

As a highly specific autacoid regulatory agent, Cetrorelix 0.25 mg Injection's core efficacy always focuses on precise regulation and inhibition of the ovulation process. This inhibitory effect is not an irreversible physiological blockade of ovulation function, nor is it a comprehensive interference with the reproductive endocrine system. Instead, it precisely intervenes in the body's reproductive endocrine pathway, targeting key links in ovulation initiation and progression, thereby achieving controllable regulation of ovulation timing.

Cetorelix COA

Certificate of Analysis
Compound name	Cetrorelix
Grade	Pharmaceutical grade
CAS No.	145672-81-7
Quantity	15g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090056
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.47%
Loss on drying	≤1.0%	0.29%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.80%
Single impurity	<0.8%	0.55%
Total microbial count	≤750cfu/g	127
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	400ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Chemical Formula	C70H92ClN17O14
Exact Mass	1429.67
Molecular Weight	1431.06
m/z	1429.67 (100.0%), 1430.67 (75.7%), 1431.67 (32.0%), 1431.68 (28.3%), 1432.67 (24.2%), 1433.67 (9.0%), 1430.67 (6.3%), 1432.68 (6.1%), 1431.67 (4.5%), 1431.67 (2.9%), 1434.68 (2.2%), 1432.68 (2.2%), 1432.66 (1.9%), 1432.67 (1.8%), 1433.67 (1.5%), 1433.68 (1.3%), 1430.68 (1.1%)
Elemental Analysis	C, 58.75; H, 6.48; Cl, 2.48; N, 16.64; O, 15.65

From the perspective of functional logic, its inhibition of ovulation is not a simple intervention in a single dimension, but a multi-level and logical regulatory process. It can be further analyzed from three core dimensions: method of action, characteristics of action, and value of action. The specific regulatory principles of ovulation process can be dismantled layer by layer, and how it achieves precise and safe inhibition of ovulation can be clearly presented.The ovulation inhibition effect of Cetrorelix 0.25 Mg Injection is based on precise intervention in the reproductive endocrine cascade, and its molecular level pathway can be broken down into two key steps, progressively achieving the inhibitory effect:

1. Competitive high affinity binding at the receptor level
It has a high degree of homology with gonadotropin-releasing autacoid in molecular structure, which allows it to competitively bind to Hypothalamic Gonadotropin-Releasing Factorreceptors on the surface of pituitary gonadotropin cells. Compared to endogenous Hypothalamic Gonadotropin-Releasing Factor, it has a stronger affinity for this receptor and does not trigger conformational changes upon binding, thus unable to activate downstream signaling pathways. This' occupying inactive 'mode directly occupies the effective binding site of the receptor, fundamentally blocking the normal interaction between endogenous Hypothalamic Gonadotropin-Releasing Factor and the receptor.

2. Dual inhibition of autacoid secretion downstream of endocrine system
When the Hypothalamic Gonadotropin-Releasing Factorreceptor is continuously occupied by it, the function of pituitary gonadotropins is rapidly regulated. On the one hand, the synthesis and pulsatile release of LH are directly suppressed, and the peak secretion of LH is the core signal that triggers follicle rupture and initiates ovulation. The absence of this signal directly terminates the ovulation initiation program; On the other hand, the basal secretion level of Follitropin is also moderately downregulated, which slows down the progression of follicular development and further cooperates with the control of ovulation timing, forming a dual inhibitory effect of "signal blockade+process regulation".

This medicine differs from traditional ovulation control agents in its core characteristics, which are reflected in its dynamic features of action. Specifically, it can be divided into two significant features, which not only ensure the inhibitory effect, but also maintain the physiological balance of the body:

1. Immediate and concentration dependent effectiveness
After subcutaneous administration, Cetrorelix 0.25 Mg Injection can be rapidly absorbed into the bloodstream through local capillaries, and the blood concentration can reach the onset threshold in a short period of time. Its inhibitory effect shows a significant concentration dependence. Within the therapeutic dose range, the higher the blood drug concentration, the higher the occupancy rate of Hypothalamic Gonadotropin-Releasing Factor receptors, and the more stable the inhibitory effect on LH and Follitropin secretion. Usually, effective blockade of ovulation initiation signals can be achieved within a few hours after administration, and regulatory effects can be exerted without long-term accumulation.

2. Reversibility of action and self stabilizing recovery of physiological functions
This inhibitory effect has strict reversibility, and the core reason is that does not accumulate in the body and is gradually cleared through liver and kidney metabolic pathways. After stopping the administration, the blood drug concentration will rapidly decrease, and the Hypothalamic Gonadotropin-Releasing Factor receptors on the surface of the pituitary gland will gradually break free from the occupation of it, restoring their binding ability with endogenous Hypothalamic Gonadotropin-Releasing Factor. Subsequently, the autacoid secretion function of the pituitary gland will gradually return to the physiological baseline, and the development rhythm and ovulation process of follicles will naturally restart, without causing irreversible damage to the long-term regulatory function of the hypothalamic pituitary ovarian axis.

By specifically antagonizing the Hypothalamic Gonadotropin-Releasing Factor, it can stably and continuously inhibit the synthesis and secretion of LH and Follitropin by the pituitary gland, effectively offsetting the interference caused by endogenous autacoid fluctuations, thereby delaying the timing of ovulation initiation, reserving sufficient and stable time windows for the full development of follicles, ensuring that follicles can gradually complete the entire maturation process within a predetermined controllable range, completely avoiding problems such as incomplete follicle development and insufficient maturity caused by early ovulation, and truly achieving precise and efficient regulation of follicle development rhythm.

In summary, the inhibitory effect of Cetrorelix 0.25 Mg Injection on ovulation is not simply a physiological blockade, but rather a precise targeted antagonism of the gonadotropin-releasing autacoid receptor, which efficiently blocks the binding of endogenous GnRH to the receptor and rapidly inhibits the secretion of luteinizing autacoid and follicle stimulating autacoid  by the pituitary gland, cutting off the signal for ovulation initiation from the source and achieving precise regulation of the ovulation process.Its core characteristics of rapid onset and reversible recovery not only ensure the high efficiency of ovulation inhibition, but also avoid long-term irreversible damage to the hypothalamic pituitary ovarian axis of the body, balancing regulatory effects and physiological safety.

The precise control of ovulation timing effectively avoids the risk of premature ovulation, provides stable time guarantee for the complete maturation of follicles, and fundamentally optimizes the quality of ovulation regulation. Looking ahead to the future, with the continuous innovation of reproductive endocrine regulation technology and the deepening of precision medicine concepts, the application of it in the field of ovulation suppression will usher in broader development space. It is expected to further improve the accuracy, safety, and convenience of ovulation suppression through the optimization of formulation processes and precise iteration of drug delivery plans.

Providing more efficient and personalized solutions for ovulation timing regulation. At the same time, relying on continuous breakthroughs in related basic research, this is expected to provide important support for technological innovation in the field of ovulation regulation, promote the entire ovulation regulation field to move towards a more precise, safe, and efficient direction, inject new vitality into related physiological regulation research and clinical applications, help achieve comprehensive and refined control of the ovulation process, and contribute important strength to the development of human reproductive health.

• When will this drug be injected?

Usually, subcutaneous injection is started after the follicle develops to a certain stage, administered daily at a fixed time, and continuously used until the ovulation inhibition target is achieved. The overall medication cycle is short and the timing is controllable.

• What are the side effects of it?

This medicine has good overall safety, with local reactions being the main cause and mild systemic reactions.
Whole body: Occasional headaches, nausea, fatigue, and emotional fluctuations can generally be relieved on their own.
Rare: Allergic reactions, abdominal pain, hot flashes, etc., with obvious discomfort requiring timely treatment.

Hot Tags: cetrorelix 0.25 mg injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale